Jenkem Technology Co Ltd
SSE:688356
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
50.7
112.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Jenkem Technology Co Ltd
SSE:688356
|
6.4B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223.2B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.1B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Jenkem Technology Co Ltd
Glance View
Jenkem Technology Co., Ltd. engages in the research, development, production and sales of medical polyethylene glycol (PEG) and its active derivatives. The company is headquartered in Beijing, Beijing and currently employs 208 full-time employees. The company went IPO on 2020-08-26. The firm's primary products are medical polyethylene glycol and its active derivatives, which are used in research, development and production of drugs and medial devices, scientific research institutions and other fields. The firm is also involved in providing technical services, including patent and non-patent technology licensing services, as well as research and development services.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Jenkem Technology Co Ltd is 7.4%, which is below its 3-year median of 29.1%.
Over the last 3 years, Jenkem Technology Co Ltd’s Operating Margin has decreased from 51.1% to 7.4%. During this period, it reached a low of 7.4% on Jul 30, 2025 and a high of 51.1% on May 30, 2022.